International journal of hematology
Emicizumab enhances the ex vivo coagulant potential in plasma samples from patients with von Willebrand disease.
Mutsumi Yabe, Shoko Furukawa, Masahiro Takeyama, Kana Sasai, Naruto Shimonishi, Yuto Nakajima, Kenichi Ogiwara, Keiji Nogami
Published: 202510.1007/s12185-025-04098-7
Abstract
BACKGROUND: von Willebrand disease (VWD) is a hereditary bleeding disorder caused by quantitative or qualitative deficiencies in von Willebrand factor (VWF). Our previous studies demonstrated that emicizumab, a bispecific monoclonal antibody that mim…
Preview only. Read the full abstract at the source